Takeda Confirms Significant Hypoglycemic Effect In Novel Diabetes Drug Fasiglifam
This article was originally published in PharmAsia News
Executive Summary
Takeda announced significant hypoglycemic effect of its new type 2 diabetes drug fasiglifam in domestic Phase III trials on diabetes at the Japan Diabetes Society Meeting.
You may also be interested in...
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.
More Heartmate Troubles For Abbott. Latest Recall Includes 14 Deaths
Abbott initiated a recall in February of thousands of Heartmate devices due to a system obstruction that can result in serious health outcomes, including death. The FDA has now designated the recall as class I.
‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs
As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments under the new Health Technology Assessment Regulation. Market access experts from EFPIA tell the Pink Sheet that this short deadline could delay patient access to complex medicines, such as innovative cancer drugs.